CL592 (cAIMP) - STING Agonist

cAIMP - STING ligand

InvivoGen's cAIMP (also known as CL592) is a novel STING (stimulator of interferon genes)-activating synthetic cyclic dinucleotide (CDN) [1].

It is an analog of the bacterial CDN 3’3’-cGAMP. Unlike natural CDNs, whose constituent nucleosides are guanosine and/or adenine, cAIMP contains one adenine nucleoside and one inosine nucleoside.

STING ligands such as cAIMP induce the production of type I interferons (IFNs) and of proinflammatory cytokines through the IRF and NF-κB pathways, respectively. 

Interestingly, when compared to the reference agonists for human (2’3’‑cGAMP) and murine (DMXAA) STING, cAIMP (referred to as compound 9 by Lioux et al.  [1]) exhibits potency similar to 2’3’-cGAMP and is more potent than DMXAA in inducing interferon regulatory factor (IRF) and NF-κB pathways in a STING‑dependent manner [1].

To facilitate the study of STING ligands, InvivoGen has developed stable reporter cells in two well established immune cell models: THP-1 human monocytes and RAW 264.7 murine macrophages. These cells express inducible SEAP and/or Lucia luciferase reporter genes under the control of an IRF-inducible and NF-κB promoter.

Reference:

1. Lioux T. et al., 2016. Design, synthesis, and biological evaluation of novel cyclic adenosine-inosine monophosphate (cAIMP) analogs that activate stimulator of interferon genes (STING). J Med Chem. 59(22):10253-10267.